الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL) are lymphoproliferative disorders representing fewer than 8% of all malignancies but whose incidence has recently been rising by 3%–5% per year (Segall 2001). These malignancies are potentially curable with current treatment modalities, even in advanced or recurrent disease. The prognosis and survival of patients with lymphoma depend on 3 key points, 2 of which are determined at the moment of diagnosis: histological grade and clinical stage. The third is response to treatment. Precise staging is crucial to the proper selection of therapy for these patients, to prevent over- or under treatment (Rodriguez-Vigil et al, 2006). Imaging traditionally has played an integral role in the initial staging and surveillance of lymphoma, primarily through the use of CT for detection of sites of disease and monitoring of morphologic changes after treatment (Cronin et al, 2010). Positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose (FDG) is used for staging and follow-up examinations in patients with Hodgkin disease and non-Hodgkin lymphoma. In comparison with morphologic imaging with contrast material–enhanced computed tomography (CT), metabolic imaging with FDG PET showed a higher specificity in the staging of disease (Moog et al, 1998)
Role of PET/CT in Lymphoma Summary
88
Over the last 10-15 years PET scanning has emerged as a powerful imaging modality in the assessment of patients with both Hodgkin’s & non-Hodgkin’s lymphoma. PET/CT is not only used to identify sites of residual disease after therapy but is a useful tool in staging, restaging, identifying potential biopsy sites & quantifying the response to therapy. Since a PET/CT scan can be used to image the whole body it gives an accurate anatomical distribution of the disease burden within the patient, allowing the appropriate therapeutic pathway to be chosen (Drake et al, 2007). Optimal management of lymphoma requires that the interpreting radiologist be familiar with the role of PET/CT in baseline staging and assessment of therapeutic response, be aware of the imaging pitfalls that may be encountered, and understand the natural behavior of lymphoma and the therapeutic options available. The most effective use of PET/CT therefore requires multidisciplinary collaboration between radiologist, clinical oncologist, and radiation oncologist (Cronin et al, 2010